Prosecution Insights
Last updated: April 19, 2026

Sorrento Therapeutics Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18008947 Administration of Resiniferatoxin For Treatment of Bladder Pain or Bladder Cancer ANDERSON, JAMES D 1629 Non-Final OA Nov 22, 2023
18561529 Presurgical Perineural Administration of Resiniferatoxin For Reduction of Post-Operative Pain RAO, SAVITHA M 1691 Non-Final OA Nov 16, 2023
17915444 Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin CORNET, JEAN P 1628 Non-Final OA Apr 28, 2023
18248079 CD19-Directed Chimeric Antigen Receptor Constructs GAMETT, DANIEL C 1647 Non-Final OA Apr 06, 2023
17830865 PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF CHATTIN, AMY MARIE 1643 Final Rejection Jun 02, 2022

Managing Sorrento Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month